ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0958

Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors

Christina Charles-Schoeman1, Maya Buch2, Maxime Dougados3, Deepak L Bhatt4, Jon Giles5, Ivana Vranic6, Joseph Wu7, Cunshan Wang7, Sujatha Menon7, Jose L Rivas8, Arne Yndestad9, Carol A Connell7 and Zoltan Szekanecz10, 1Department of Medicine, University of California, Los Angeles, Los Angeles, CA, 2University of Leeds, Leeds, United Kingdom, 3Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, 4Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 5Columbia University, New York, NY, 6Pfizer Inc, Tadworth, Surrey, United Kingdom, 7Pfizer Inc, Groton, CT, 8Pfizer SLU, Madrid, Spain, 9Pfizer Inc, Oslo, Norway, 10Division of Rheumatology, University of Debrecen, Faculty of Medicine, Debrecen, Hungary

Meeting: ACR Convergence 2021

Keywords: Anti-TNF Drugs, Cardiovascular, clinical trial, Disease-Modifying Antirheumatic Drugs (Dmards), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 7, 2021

Title: Plenary II (0956–0961)

Session Type: Plenary Session

Session Time: 11:00AM-11:15AM

Background/Purpose: To identify independent risk factors for major adverse cardiovascular (CV) events (MACE) in ORAL Surveillance (NCT02092467), a long-term, randomized, open-label, non-inferiority, Phase 3b/4 safety study of tofacitinib vs TNFi in high-risk (aged ≥ 50 yrs with ≥ 1 additional CV risk factor) patients (pts) with RA and an inadequate MTX response.

Methods: Pts on stable doses of MTX were randomized 1:1:1 to receive tofacitinib 5 or 10 mg BID or a TNFi (adalimumab 40 mg every 2 weeks or etanercept 50 mg every week). Incidence rates (IRs; unique pts with events/100 pt-yrs) and hazard ratios (HRs; tofacitinib vs TNFi) were evaluated for the co-primary endpoint of adjudicated MACE, as well as myocardial infarction (MI) and stroke; MACE was defined as CV death (excluding CV death due to pulmonary embolism), non-fatal MI, and non-fatal stroke. Across outcomes, IRs and HRs are also presented for fatal and non-fatal events. A post hoc analysis identified independent overall risk factors for MACE across treatment groups by Cox regression models. Baseline (BL) categorical covariates were initially screened in 2 univariate Cox analyses (main risk factor p < 0.1 and risk factor–treatment interaction p ≥ 0.2) and were then selected in the final multivariate Cox model using backward selection, with p < 0.1 stay criteria. IRs and HRs for MACE were then stratified by the 4 most important risk factors identified (per largest HRs and smallest p values in the multivariate Cox model).

Results: 4,362 pts were included (tofacitinib 5 mg BID, n=1,455; tofacitinib 10 mg BID, n=1,456; TNFi, n=1,451). Median (range) age was 60.0 (50.0–88.0) yrs. MACE was reported by 47 pts, 51 pts, and 37 pts receiving tofacitinib 5 mg BID, tofacitinib 10 mg BID, and TNFi, respectively (Figure). IRs for MACE, MI, fatal and non-fatal MACE, and non‑fatal MI were numerically higher with both tofacitinib doses vs TNFi (95% CIs overlapped; Figure a, b). Generally, IRs for fatal MI, and stroke (including fatal/non-fatal events), were similar across treatment groups (Figure a–c). HRs for MACE, MI, and stroke were generally > 1 for tofacitinib vs TNFi (Figure a–c); HR 95% CIs for non-fatal MI excluded 1 for tofacitinib 5 mg BID and all tofacitinib vs TNFi. BL covariates identified as the most important independent overall risk factors for MACE were current smoking, aspirin use, age ≥ 65 yrs, and male sex (Table 1). In pts with 1 of these risk factors present, IRs for MACE were numerically higher with both tofacitinib doses vs TNFi (95% CIs overlapped; Table 2). Across treatment groups, in pts without these risk factors present, IRs for MACE were similar (Table 2). Generally, HRs for MACE were > 1 for tofacitinib vs TNFi, in pts with or without risk factors present (Table 2).

Conclusion: The incidence of MACE was numerically higher with tofacitinib vs TNFi treatment. Across treatment groups, the BL covariates, current smoking, aspirin use, age ≥ 65 yrs, and male sex were identified as independent overall risk factors in pts experiencing MACE; tofacitinib vs TNFi treatment in pts with any of these risk factors present was associated with numerically higher incidence of MACE.

Acknowledgments: Study sponsored by Pfizer Inc. Medical writing support was provided by K Woollcott, CMC Connect, funded by Pfizer Inc.


Disclosures: C. Charles-Schoeman, AbbVie, 2, 5, Bristol-Myers Squibb, 5, Pfizer Inc, 2, 5, Gilead Sciences, 2, Sanofi-Regeneron, 2; M. Buch, AbbVie, 2, 5, 6, Gilead Sciences, 2, 5, 6, Pfizer Inc, 2, 5, 6, UCB, 2, 5, 6, Eli Lilly, 2, 5, 6, MSD, 2, 5, 6, Roche, 2, 5, Sanofi, 2, 5, 6; M. Dougados, AbbVie, 2, 5, Bristol-Myers Squibb, 2, 5, Eli Lilly, 2, 5, Merck, 2, 5, Novartis, 2, 5, Pfizer Inc, 2, 5, Roche, 2, 5, UCB, 2, 5; D. Bhatt, Pfizer Inc, 2, 5, Abbott, 5, Afimmune, 5, Amarin, 5, Amgen, 5, AstraZeneca, 5, Bayer, 5, Boehringer Ingelheim, 5, Bristol-Myers Squibb, 5, Cardax, 5, Chiesi, 5, CSL Behring, 5, Eisai, 5, Eli Lilly, 5, Ethicon, 5, Ferring Pharmaceuticals, 5, Forest Laboratories, 5, Fractyl, 5, HLS Therapeutics, 5, Idorsia, 5, Ironwood, 5, Ischemix, 5, Lexicon, 5, Medtronic, 5, MyoKardia, 5, Owkin, 5, Novo Nordisk, 5, PhaseBio, 5, PLx Pharma, 5, Regeneron, 5, Roche, 5, Sanofi, 5, Synaptic, 5, The Medicines Company, 5; J. Giles, AbbVie, 2, Bristol-Myers Squibb, 2, Eli Lilly, 2, Genentech, 2, Gilead Sciences, 2, UCB, 2, Pfizer Inc, 5; I. Vranic, Pfizer Inc, 3, 11; J. Wu, Pfizer Inc, 3, 11; C. Wang, Pfizer Inc, 3, 11; S. Menon, Pfizer Inc, 3, 11; J. Rivas, Pfizer Inc, 3, 11; A. Yndestad, Pfizer Inc, 3, 11; C. Connell, Pfizer Inc, 3, 11; Z. Szekanecz, AbbVie, 1, 2, 6, Eli Lilly, 1, 2, 6, Gedeon Richter, 1, Pfizer Inc, 1, 2, 5, 6, Roche, 1, 2, 6, Sanofi, 2, 6, Novartis, 1, 2, 6.

To cite this abstract in AMA style:

Charles-Schoeman C, Buch M, Dougados M, Bhatt D, Giles J, Vranic I, Wu J, Wang C, Menon S, Rivas J, Yndestad A, Connell C, Szekanecz Z. Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Years with RA and ≥ 1 Additional Cardiovascular Risk Factor: Results from a Phase 3b/4 Randomized Safety Study of Tofacitinib vs TNF Inhibitors [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/risk-factors-for-major-adverse-cardiovascular-events-in-patients-aged-%e2%89%a5-50-years-with-ra-and-%e2%89%a5-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-stud/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-factors-for-major-adverse-cardiovascular-events-in-patients-aged-%e2%89%a5-50-years-with-ra-and-%e2%89%a5-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-stud/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology